ClinicalTrials.gg
CompletedNCT03567434Updated Sep 24, 2024Results posted

Alcohol and Neural Cardiovascular Control in Binge Drinkers

An interventional study of Alcohol vs. Placebo in Binge Drinking, sponsored by Baylor University. Completed at 1 site in United States. Open to participants aged 21 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Baylor University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
21 Years to 40 Years
Sex
All
01

Study summary

This study evaluates the impact of evening alcohol consumption on sympathetic activity and baroreflex function in binge drinkers. Our central hypothesis is that evening binge alcohol consumption will lead to sympathetic overactivity and blunted baroreflex function.

Read the detailed description

This study will recruit male and female binge drinkers who will participate in a randomized, cross-over, double-blind, placebo-based study to examine the impact of an evening of alcohol vs. placebo/fluid-control on autonomic and cardiovascular control at night and the subsequent morning. The study will utilize established techniques for assessing sleep (polysomnography) and autonomic/cardiovascular control (microneurography, beat-to-beat finger plethysmography, electrocardiogram, etc.). All subjects will undergo a familiarization night in the sleep laboratory prior to their first randomized test session with either alcohol or placebo/fluid-control. Both men and women will be tested to address a secondary aim of determining the impact of sex (male vs. female) and ovarian cycle (early follicular vs. midluteal phase) on sympathetic neural responsiveness to evening alcohol in binge drinkers. Finally, as a tertiary/exploratory aim, participants that have a respiratory disturbance index of ≥5 episodes per hour during the alcohol treatment will be asked to consider one additional overnight session where they will be randomly assigned to either continuous positive airway pressure (CPAP) or sham-CPAP for one additional night of evening alcohol consumption.

02

Conditions studied

  • Binge Drinking

Browse trials for

03

In context

Binge Drinking

71 studies on the registry are indexed under Binge Drinking; 20 are open to participants now.

This study's enrollment of 69 is below the median of 120 across 64 interventional studies indexed under Binge Drinking.

Browse Binge Drinking studies →

Lead sponsor

Baylor University is the lead sponsor of 42 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women age 21 - 40 years
  • Binge drinkers as defined by a pattern of consuming ≥4 drinks if female (≥5 drinks if males) in ≤ 2 hours on more than one occasion within the past 6 months, and at least once in the past 30 days. The National Institute of Alcohol Abuse and Alcoholism (NIAAA) definition of a "drink" will be used.
  • Women must be eumenorrheic and premenopausal with regular and consistent menstrual cycles (i.e., \~25-30 days ovarian/uterine cycles that include 2-7 days of menstruation)
  • Willingness to abstain from exercise and caffeine at least 12 hours prior to any autonomic and cardiovascular testing, and abstain from alcohol 24 hours prior to any autonomic and cardiovascular testing (unless experimentally administered).

Exclusion criteria

Exclusion Criteria:

  • ≥ 35 kg/m2
  • Smokers
  • A physician diagnosis of diabetes
  • Pregnancy
  • Taking any cardiovascular medications
  • Severe obstructive sleep apnea as determined by an apnea-hypopnea index of ≥ 30 episodes per hour
  • Moderate-to-severe Alcohol Use Disorder (AUD) as determined by the (DSM-V)
  • Individuals suspected to have mutant alcohol dehydrogenase 2 (ALDH2) isoenzyme as determined using a validated flushing questionnaire
  • Women using hormonal (i.e., oral, intrauterine, etc.) in the prior 6 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
69 participants (actual)

Study arms

  • Placebo comparator
    Fluid Control

    Participants first received a fluid control drink (i.e., juice) of the same volume of fluid as the alcohol condition. After at least a one-month washout period, they then received the alcohol condition.

    Other: Alcohol vs. Placebo

  • Experimental
    Alcohol

    Participants first received the alcohol condition with 95% ethanol and fruit juice (1:3 ratio). After at least a one-month washout period, they then received the fluid control condition with a volume fluid match.

    Other: Alcohol vs. Placebo

Interventions

  • OtherAlcohol vs. Placebo

    Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.

    Also known as: Ethanol

06

What researchers measure

Primary outcomes

  1. Sympathetic Nerve Activity Burst Frequency

    Direct recordings of muscle sympathetic nerve activity (MSNA) from the peroneal nerve using a microelectrode.

    Time frame: 1 month

  2. Sympathetic Nerve Activity Burst Incidence

    Direct recordings of muscle sympathetic nerve activity (MSNA) from the peroneal nerve using a microelectrode. Burst incidence is calculated as the number of sympathetic bursts per 100 heartbeats. This measure takes into account varying heart rates on sympathetic activity by normalizing to each individual's heartbeat. Higher calculated number equates to higher sympathetic activity.

    Time frame: 1 month

Secondary outcomes

  1. Spontaneous Sympathetic Baroreflex Sensitivity

    The linear relationship between beat-to-beat blood pressure and sympathetic nerve activity expressed as bursts/100 heart beats. Sympathetic baroreflex sensitivity is determined using the slope of the weighted linear regression of diastolic blood pressure and MSNA burst incidence. Diastolic blood pressure values of individual cardiac cycles were binned into 3 mmHg intervals, and the MSNA burst incidence was determined and subsequently plotted against corresponding diastolic blood pressure bins.

    Time frame: 1 month

Other outcomes

  1. Nocturnal Blood Pressure Dip

    Change in nocturnal blood pressure during sleep when compared to evening/morning wakefulness.

    Time frame: 1 month

  2. Sleep Quality

    Polysomnography will be used to determine the quality of sleep, with a primary focus on the apnea-hypopnea index.

    Time frame: 1 month

  3. Sympathetic Reactivity

    The change in muscle sympathetic nerve activity during an acute laboratory stressor.

    Time frame: 1 month

07

Results

Posted Aug 29, 2024

Participant flow

Participants were recruited by word-of-mouth and advertisements. 169 participants were screened for eligibility.

Participant flow — Overall Study
MilestoneFluid Control, Then AlcoholAlcohol, Then Fluid Control
Started1622
Completed test 11622
Completed test 21519
Completed1519
Not completed13
Withdrew: Lost to follow-up13

Outcome measures

PrimarySympathetic Nerve Activity Burst Frequency

Direct recordings of muscle sympathetic nerve activity (MSNA) from the peroneal nerve using a microelectrode.

Time frame:
1 month
Reported as:
Mean · Burst/Min
Sympathetic Nerve Activity Burst Frequency
Burst/MinFluid ControlAlcohol
Sympathetic Nerve Activity Burst Frequency18 ± 920 ± 8
Statistical analysis
  • Fluid Control vs Alcohol · t-test, 2 sided · p = 0.283 (The original hypothesis was that resting MSNA burst frequency would be higher the morning after evening binge alcohol when compared to fluid control condition. A p-value of \< 0.05 was used for significance.)
  • Fluid Control vs Alcohol · t-test, 2 sided · p = 0.920 (The original hypothesis was that resting MSNA burst frequency would be higher the morning after evening binge alcohol when compared to fluid control condition. A p-value of \< 0.05 was used for significance.)
PrimarySympathetic Nerve Activity Burst Incidence

Direct recordings of muscle sympathetic nerve activity (MSNA) from the peroneal nerve using a microelectrode. Burst incidence is calculated as the number of sympathetic bursts per 100 heartbeats. This measure takes into account varying heart rates on sympathetic activity by normalizing to each individual's heartbeat. Higher calculated number equates to higher sympathetic activity.

Time frame:
1 month
Reported as:
Mean · burst/100 heart beats
Sympathetic Nerve Activity Burst Incidence
burst/100 heart beatsFluid ControlAlcohol
Sympathetic Nerve Activity Burst Incidence31 ± 1631 ± 12
SecondarySpontaneous Sympathetic Baroreflex Sensitivity

The linear relationship between beat-to-beat blood pressure and sympathetic nerve activity expressed as bursts/100 heart beats. Sympathetic baroreflex sensitivity is determined using the slope of the weighted linear regression of diastolic blood pressure and MSNA burst incidence. Diastolic blood pressure values of individual cardiac cycles were binned into 3 mmHg intervals, and the MSNA burst incidence was determined and subsequently plotted against corresponding diastolic blood pressure bins.

Time frame:
1 month
Reported as:
Mean · MSNA Bursts/100 heart beats/mmHg
Spontaneous Sympathetic Baroreflex Sensitivity
MSNA Bursts/100 heart beats/mmHgFluid ControlAlcohol
Spontaneous Sympathetic Baroreflex Sensitivity-2 ± 1-2 ± 1
Statistical analysis
  • Fluid Control vs Alcohol · t-test, 2 sided · p = 0.888 (The original hypothesis was that sympathetic baroreflex sensitivity would be blunted the morning after evening binge alcohol when compared to fluid control condition. A p-value of \< 0.05 was used for significance.)
Other pre-specifiedNocturnal Blood Pressure Dip

Change in nocturnal blood pressure during sleep when compared to evening/morning wakefulness.

Time frame:
1 month

Results for this outcome have not been posted.

Other pre-specifiedSleep Quality

Polysomnography will be used to determine the quality of sleep, with a primary focus on the apnea-hypopnea index.

Time frame:
1 month

Results for this outcome have not been posted.

Other pre-specifiedSympathetic Reactivity

The change in muscle sympathetic nerve activity during an acute laboratory stressor.

Time frame:
1 month

Results for this outcome have not been posted.

Adverse events

Collected over On average 1 to 2 months following initial laboratory testing session. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluid Control—0/38 (0%)2/38 (5.3%)
Alcohol—0/38 (0%)1/38 (2.6%)
Most frequent other events
Most frequent other events
EventFluid ControlAlcohol
Presyncope in response to venipunctureNervous system disorders2/380/38
NauseaGastrointestinal disorders0/381/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Fluid Control, Then AlcoholAlcohol, Then Fluid ControlTotal
<=18 years000
Between 18 and 65 years162238
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Fluid Control, Then AlcoholAlcohol, Then Fluid ControlTotal
Female91221
Male71017
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fluid Control, Then AlcoholAlcohol, Then Fluid ControlTotal
Hispanic or Latino134
Not Hispanic or Latino131932
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fluid Control, Then AlcoholAlcohol, Then Fluid ControlTotal
American Indian or Alaska Native000
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American000
White131932
More than one race000
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)Fluid Control, Then AlcoholAlcohol, Then Fluid ControlTotal
United States162238
08

Study locations

1 site
  • Montana State University
    Bozeman, Montana 59717, United States
09

References and documents

Publications

  • Greenlund IM, Bigalke JA, Tikkanen AL, Durocher JJ, Smoot CA, Carter JR. Evening binge alcohol disrupts cardiovagal tone and baroreflex function during polysomnographic sleep. Sleep. 2021 Nov 12;44(11):zsab130. doi: 10.1093/sleep/zsab130. PubMed 34015116 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The scientific field of neural cardiovascular control in humans does not, at present, have a common data repository that would be applicable to this project. However, all data will be stored on secure University server in a de-identified manner, and investigators will make raw data available to individuals, groups, and organizations upon request and when appropriate.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jul 2022, 49 months.

Results were first posted in Aug 2024, 2 years 1 month after primary completion.

Of 38 interventional studies with no phase under Binge Drinking, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 25, 2018
StartActual
May 21, 2018
Primary completionActual
Jul 1, 2022
CompletionActual
Jul 1, 2022
Results first posted
Aug 29, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03567434
Lead sponsor
Baylor University
Responsible party
Sponsor
First posted
Jun 25, 2018
Start date
May 21, 2018
Primary completion
Jul 1, 2022
Completion
Jul 1, 2022
Results posted
Aug 29, 2024
Last update
Sep 24, 2024

Study contacts

Jason Carter
principal investigator · Baylor University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion